Tetra Med Sciences starts operations
- To work on new molecule development
Tetra Med Sciences founded by Rama S Eyunni and Ms. Lathaa Subramanian with a vision to enhance access to affordable healthcare with new molecule development to help humanity to lead healthy lives. We are also committed to the 2030 vision of Gulf and Asian countries in the pharmaceutical world. Tetra Med Sciences started with a small team of 10 technical people with rich R&D experience.
The initial focus will be on developing molecules with their intermediates for APIs and going off-patent now and in coming 5 -10 years; and after getting drug license – work on finished API doses also. The company aims to work on API and other domains; and plans to acquire their own production facility center at the earliest but for now has signed a 3rd party facility for immediate needs. The company is currently working on molecules for pharma and plans to roll out cost competent and non-infringing intermediates. The team has expertise in the fields of drug discovery, medicinal chemistry besides aroma chemicals.
Speaking on the occasion, Ms. Sunita Eyunni, Director, Tetra Med Sciences, said, “Covid19 impacted global supply chains especially in the pharma sector given the huge dependence on API from China; molecule development and formulation of drugs became a huge challenge not just in India but globally as well. As cost, quality & timely deliveries are critical components of the supply chain - Covid19 impact jeopardized the production schedule of pharma firms. Our new R&D Center at Hyderabad, the pharma hub of India is an important step in our commitment to the Government of India’s Atmanirbhar vision.”
Ms. Lathaa Subramanian, Founder, Tetra Med Sciences added, “Recognizing the impact of API supply chain shortage and cost competency of pharma sector and encouraged by Govt. support for women entrepreneurs; we decided to work in new molecules development starting with intermediates for API. Given the huge scientific talent pool at Hyderabad, knowledge base and competitive manpower advantage, we look forward to working with pharma industry.”